The global Castrate Resistant Prostate Cancer Market is estimated to be valued at US$ 11.12 Bn in 2023 and is expected to exhibit a CAGR of 6.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Castrate resistant prostate cancer is an advanced stage of prostate cancer that does not respond to hormonal therapy. Hormonal therapy is a standard treatment for prostate cancer which reduces the amount of male sex hormones like testosterone in the body. However, in some cases prostate cancer continues to grow despite the reduction of testosterone level. The global castrate resistant prostate cancer market is growing due to increasing prevalence of prostate cancer and rising adoption of targeted therapy.
Market key trends:
The rising adoption of targeted therapy is one of the major trends boosting the growth of castrate resistant prostate cancer market. Targeted therapy is a type of cancer treatment that uses drugs or other substances to identify and attack specific types of cancer cells with more precision than standard chemotherapy or radiation therapy. Targeted therapies for castrate resistant prostate cancer work by blocking the growth and spread of cancer cells. Drugs such as abiraterone, enzalutamide, Radium-223, cabazitaxel are used as targeted therapies to stop or slow the growth of prostate cancer by interfering with specific molecules involved in tumor growth and progression. The increasing success of targeted therapy in improving survival rates of castrate resistant prostate cancer patients is fueling its rising demand.
Segment Analysis
The global castrate resistant prostate cancer market is dominated by chemotherapy as a major treatment segment. Chemotherapy constitutes over 35% of the market share as it remains one of the important treatment option for patients with advanced or metastasized prostate cancer. However, the hormone therapy segment is witnessing high growth and is emerging as a promising treatment segment. This is majorly due to availability of new hormone therapy drugs which are more effective and show improved results for patients with castrate resistant prostate cancer.
Key Takeaways
The Global Castrate Resistant Prostate Cancer Market Size is expected to witness high growth over the forecast period of 2023 to 2030.
Regional analysis shows that North America currently dominates the market and is expected to continue its dominance over the forecast period. This is majorly attributed to increasing incidence of prostate cancer, availability of advanced treatment options and growing healthcare expenditure in the region.
Key players operating in the castrate resistant prostate cancer market include Bucher Vaslin, Pera Pellenc, Scharfenberger, Zambelli Enotech, ENOTOOLS, Criveller Group, Della Toffola, Gruppo Bertolaso, Fabbri, Mori Luigi & C. Among these, Bucher Vaslin and Pera Pellenc collectively account for over 30% of the market share owing to their robust product portfolio and widespread distribution network across major markets. The other key players are focusing on new product launches, collaborations and geographic expansions to strengthen their position in the market.
For More Insights, Read: https://www.newswirestats.com/castrate-resistant-prostate-cancer-market-trends-growth-and-regional-outlook-2023-2030/
Research Nester released a report titled “Non-Metastatic Castration Resistant Prostate Cancer Treatment Market: Global Demand Analysis & Opportunity Outlook 2029”which delivers detailed overview of the global non-metastatic castration resistant prostate cancer treatment market in terms of market segmentation by therapy type, application and region.Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.The non-metastatic castration resistant prostate cancer (nmCRPC) treatment market is projected to grow with a moderate CAGR during the forecast period, i.e., 2021-2029 on account of the increasing elderly population and the rising prevalence of prostate cancer.
The National Cancer Institute of the U.S. Department of Health and Human Services, in the U.S., the estimated new cases and number of deaths from prostate cancer in the year 2020 were 191,930 and 33,330, respectively.Get Exclusive Sample Report Copy Of This Report @ https://www.researchnester.com/sample-request-2884The market is segmented by therapy type into chemotherapy, immunotherapy, radiotherapy, hormonal therapy, and others.
Among these segments, the hormonal therapy segment is anticipated to hold the largest share by the end of 2021 in the nmCRPC treatment market as a result of the higher positive diagnosis rates of hormonal therapy than other available treatments.
This can be attributed to the presence of leading healthcare providers in the region, especially in the United States, who are extensively involved in the research and development for innovative cancer treatment procedures.Increasing Ageing Population and Prostate Cancer Prevalence to Drive Market GrowthAccording to the United Nations, it is estimated that by 2050, every one in six people will be 65 years or older, i.e., 16% of the total world population.
It has been observed that individuals whose age is above 65 years or more possesses a high risk of having prostate cancer.
However, the expensive cost of cancer therapies and lack of awareness in low income economies are some factors that are estimated to restrain market growth in the near future.Get Exclusive Sample Report Copy Of This Report @ https://www.researchnester.com/sample-request-2884This report also provides the existing competitive scenario of some of the key players of the global non-metastatic castration resistant prostate cancer treatment market which includes company profiling of Pfizer Inc. (NYSE: PFE), Astellas Pharma Inc. (TYO: 4503), Johnson & Johnson Health Care Systems Inc. (NYSE: JNJ), Bayer AG (ETR: BAYN), Orion Corporation (HEL: ORNBV), Merck Sharp & Dohme Corp. (NYSE: MRK), Clovis Oncology (NASDAQ: CLVS), Novartis AG (SWX: NOVN), and AstraZeneca PLC (LON: AZN).
